<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33525357</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1422-0067</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>22</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jan</Month>
              <Day>28</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of molecular sciences</Title>
          <ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Cholinergic System, the Adrenergic System and the Neuropathology of Alzheimer's Disease.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">1273</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms22031273</ELocationID>
        <Abstract>
          <AbstractText>Neurodegenerative diseases are a major public health problem worldwide with a wide spectrum of symptoms and physiological effects. It has been long reported that the dysregulation of the cholinergic system and the adrenergic system are linked to the etiology of Alzheimer's disease. Cholinergic neurons are widely distributed in brain regions that play a role in cognitive functions and normal cholinergic signaling related to learning and memory is dependent on acetylcholine. The Locus Coeruleus norepinephrine (LC-NE) is the main noradrenergic nucleus that projects and supplies norepinephrine to different brain regions. Norepinephrine has been shown to be neuroprotective against neurodegeneration and plays a role in behavior and cognition. Cholinergic and adrenergic signaling are dysregulated in Alzheimer's disease. The degeneration of cholinergic neurons in nucleus basalis of Meynert in the basal forebrain and the degeneration of LC-NE neurons were reported in Alzheimer's disease. The aim of this review is to describe current literature on the role of the cholinergic system and the adrenergic system (LC-NE) in the pathology of Alzheimer's disease and potential therapeutic implications.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bekdash</LastName>
            <ForeName>Rola A</ForeName>
            <Initials>RA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biological Sciences, Rutgers University, Newark, NJ 07102, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>01</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int J Mol Sci</MedlineTA>
        <NlmUniqueID>101092791</NlmUniqueID>
        <ISSNLinking>1422-0067</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011976">Receptors, Muscarinic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011978">Receptors, Nicotinic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>N9YNS0M02X</RegistryNumber>
          <NameOfSubstance UI="D000109">Acetylcholine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>X4W3ENH1CV</RegistryNumber>
          <NameOfSubstance UI="D009638">Norepinephrine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000109" MajorTopicYN="N">Acetylcholine</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059331" MajorTopicYN="N">Adrenergic Neurons</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020532" MajorTopicYN="N">Basal Nucleus of Meynert</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059329" MajorTopicYN="N">Cholinergic Neurons</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008125" MajorTopicYN="N">Locus Coeruleus</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009638" MajorTopicYN="N">Norepinephrine</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011976" MajorTopicYN="N">Receptors, Muscarinic</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011978" MajorTopicYN="N">Receptors, Nicotinic</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Alzheimer</Keyword>
        <Keyword MajorTopicYN="N">Locus Coeruleus</Keyword>
        <Keyword MajorTopicYN="N">acetylcholine</Keyword>
        <Keyword MajorTopicYN="N">adrenergic</Keyword>
        <Keyword MajorTopicYN="N">cholinergic</Keyword>
        <Keyword MajorTopicYN="N">cognition</Keyword>
        <Keyword MajorTopicYN="N">epigenetics</Keyword>
        <Keyword MajorTopicYN="N">norepinephrine</Keyword>
        <Keyword MajorTopicYN="N">signaling</Keyword>
      </KeywordList>
      <CoiStatement>The author declares no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>2</Day>
          <Hour>1</Hour>
          <Minute>3</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33525357</ArticleId>
        <ArticleId IdType="pmc">PMC7865740</ArticleId>
        <ArticleId IdType="doi">10.3390/ijms22031273</ArticleId>
        <ArticleId IdType="pii">ijms22031273</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Hebert L.E., Weuve J., Scherr P.A., Evans D.A. Alzheimer Disease in the United States (2010–2050) Estimated Using the 2010 Census. Neurology. 2013;80:1778–1783. doi: 10.1212/WNL.0b013e31828726f5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e31828726f5</ArticleId>
            <ArticleId IdType="pmc">PMC3719424</ArticleId>
            <ArticleId IdType="pubmed">23390181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Products—Data Briefs—Number 355—January 2020.  [(accessed on 7 October 2020)]; Available online:  https://www.cdc.gov/nchs/products/databriefs/db355.htm.</Citation>
        </Reference>
        <Reference>
          <Citation>Wenk G.L. Neuropathologic Changes in Alzheimer’s Disease. J. Clin. Psychiatry. 2003;64(Suppl. 9):7–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12934968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calderon-Garcidueñas A.L., Duyckaerts C. Alzheimer Disease. Handb. Clin. Neurol. 2017;145:325–337. doi: 10.1016/B978-0-12-802395-2.00023-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/B978-0-12-802395-2.00023-7</ArticleId>
            <ArticleId IdType="pubmed">28987180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hampel H., Mesulam M.-M., Cuello A.C., Farlow M.R., Giacobini E., Grossberg G.T., Khachaturian A.S., Vergallo A., Cavedo E., Snyder P.J., et al.  The Cholinergic System in the Pathophysiology and Treatment of Alzheimer’s Disease. Brain. 2018;141:1917–1933. doi: 10.1093/brain/awy132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awy132</ArticleId>
            <ArticleId IdType="pmc">PMC6022632</ArticleId>
            <ArticleId IdType="pubmed">29850777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ross J.A., McGonigle P., Van Bockstaele E.J. Locus Coeruleus, Norepinephrine and Aβ Peptides in Alzheimer’s Disease. Neurobiol Stress. 2015;2:73–84. doi: 10.1016/j.ynstr.2015.09.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ynstr.2015.09.002</ArticleId>
            <ArticleId IdType="pmc">PMC4657149</ArticleId>
            <ArticleId IdType="pubmed">26618188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woolf N.J., Butcher L.L. Cholinergic Systems Mediate Action from Movement to Higher Consciousness. Behav. Brain Res. 2011;221:488–498. doi: 10.1016/j.bbr.2009.12.046.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbr.2009.12.046</ArticleId>
            <ArticleId IdType="pubmed">20060422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinshenker D. Long Road to Ruin: Noradrenergic Dysfunction in Neurodegenerative Disease. Trends Neurosci. 2018;41:211–223. doi: 10.1016/j.tins.2018.01.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tins.2018.01.010</ArticleId>
            <ArticleId IdType="pmc">PMC5878728</ArticleId>
            <ArticleId IdType="pubmed">29475564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Picciotto M.R., Higley M.J., Mineur Y.S. Acetylcholine as a Neuromodulator: Cholinergic Signaling Shapes Nervous System Function and Behavior. Neuron. 2012;76:116–129. doi: 10.1016/j.neuron.2012.08.036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuron.2012.08.036</ArticleId>
            <ArticleId IdType="pmc">PMC3466476</ArticleId>
            <ArticleId IdType="pubmed">23040810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hasselmo M.E., Sarter M. Modes and Models of Forebrain Cholinergic Neuromodulation of Cognition. Neuropsychopharmacology. 2011;36:52–73. doi: 10.1038/npp.2010.104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/npp.2010.104</ArticleId>
            <ArticleId IdType="pmc">PMC2992803</ArticleId>
            <ArticleId IdType="pubmed">20668433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gill S.K., Ishak M., Dobransky T., Haroutunian V., Davis K.L., Rylett R.J. 82-KDa Choline Acetyltransferase Is in Nuclei of Cholinergic Neurons in Human CNS and Altered in Aging and Alzheimer Disease. Neurobiol. Aging. 2007;28:1028–1040. doi: 10.1016/j.neurobiolaging.2006.05.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neurobiolaging.2006.05.011</ArticleId>
            <ArticleId IdType="pubmed">16797789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wurtman R.J. Choline Metabolism as a Basis for the Selective Vulnerability of Cholinergic Neurons. Trends Neurosci. 1992;15:117–122. doi: 10.1016/0166-2236(92)90351-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0166-2236(92)90351-8</ArticleId>
            <ArticleId IdType="pubmed">1374967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bartus R.T., Dean R.L., Beer B., Lippa A.S. The Cholinergic Hypothesis of Geriatric Memory Dysfunction. Science. 1982;217:408–414. doi: 10.1126/science.7046051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.7046051</ArticleId>
            <ArticleId IdType="pubmed">7046051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D’Alton S., George D.R. Changing Perspectives on Alzheimer’s Disease: Thinking Outside the Amyloid Box. J. Alzheimers Dis. 2011;25:571–581. doi: 10.3233/JAD-2011-110089.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/JAD-2011-110089</ArticleId>
            <ArticleId IdType="pubmed">21460435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hampel H., Mesulam M.-M., Cuello A.C., Khachaturian A.S., Vergallo A., Farlow M.R., Snyder P.J., Giacobini E., Khachaturian Z.S. Revisiting the Cholinergic Hypothesis in Alzheimer’s Disease: Emerging Evidence from Translational and Clinical Research. J. Prev. Alzheimers Dis. 2019;6:2–15. doi: 10.1016/j.jalz.2017.08.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jalz.2017.08.016</ArticleId>
            <ArticleId IdType="pubmed">30569080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karran E., Mercken M., De Strooper B. The Amyloid Cascade Hypothesis for Alzheimer’s Disease: An Appraisal for the Development of Therapeutics. Nat. Rev. Drug Discov. 2011;10:698–712. doi: 10.1038/nrd3505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrd3505</ArticleId>
            <ArticleId IdType="pubmed">21852788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Contestabile A. The History of the Cholinergic Hypothesis. Behav. Brain Res. 2011;221:334–340. doi: 10.1016/j.bbr.2009.12.044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbr.2009.12.044</ArticleId>
            <ArticleId IdType="pubmed">20060018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whitehouse P.J., Price D.L., Clark A.W., Coyle J.T., DeLong M.R. Alzheimer Disease: Evidence for Selective Loss of Cholinergic Neurons in the Nucleus Basalis. Ann. Neurol. 1981;10:122–126. doi: 10.1002/ana.410100203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410100203</ArticleId>
            <ArticleId IdType="pubmed">7283399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whitehouse P.J., Price D.L., Struble R.G., Clark A.W., Coyle J.T., Delon M.R. Alzheimer’s Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain. Science. 1982;215:1237–1239. doi: 10.1126/science.7058341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.7058341</ArticleId>
            <ArticleId IdType="pubmed">7058341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferreira-Vieira T.H., Guimaraes I.M., Silva F.R., Ribeiro F.M. Alzheimer’s Disease: Targeting the Cholinergic System. Curr. Neuropharmacol. 2016;14:101–115. doi: 10.2174/1570159X13666150716165726.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1570159X13666150716165726</ArticleId>
            <ArticleId IdType="pmc">PMC4787279</ArticleId>
            <ArticleId IdType="pubmed">26813123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parnetti L., Amici S., Lanari A., Romani C., Antognelli C., Andreasen N., Minthon L., Davidsson P., Pottel H., Blennow K., et al.  Cerebrospinal Fluid Levels of Biomarkers and Activity of Acetylcholinesterase (AChE) and Butyrylcholinesterase in AD Patients before and after Treatment with Different AChE Inhibitors. Neurol. Sci. 2002;23(Suppl. 2):S95–S96. doi: 10.1007/s100720200086.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s100720200086</ArticleId>
            <ArticleId IdType="pubmed">12548360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma K. Cholinesterase Inhibitors as Alzheimer’s Therapeutics (Review) Mol. Med. Rep. 2019;20:1479–1487. doi: 10.3892/mmr.2019.10374.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/mmr.2019.10374</ArticleId>
            <ArticleId IdType="pmc">PMC6625431</ArticleId>
            <ArticleId IdType="pubmed">31257471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnston M.V., McKinney M., Coyle J.T. Evidence for a Cholinergic Projection to Neocortex from Neurons in Basal Forebrain. Proc. Natl. Acad. Sci. USA. 1979;76:5392–5396. doi: 10.1073/pnas.76.10.5392.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.76.10.5392</ArticleId>
            <ArticleId IdType="pmc">PMC413149</ArticleId>
            <ArticleId IdType="pubmed">388436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X.-Q., Mobley W.C. Exploring the Pathogenesis of Alzheimer Disease in Basal Forebrain Cholinergic Neurons: Converging Insights from Alternative Hypotheses. Front. Neurosci. 2019;13 doi: 10.3389/fnins.2019.00446.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnins.2019.00446</ArticleId>
            <ArticleId IdType="pmc">PMC6514132</ArticleId>
            <ArticleId IdType="pubmed">31133787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ballinger E.C., Ananth M., Talmage D.A., Role L.W. Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline. Neuron. 2016;91:1199–1218. doi: 10.1016/j.neuron.2016.09.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuron.2016.09.006</ArticleId>
            <ArticleId IdType="pmc">PMC5036520</ArticleId>
            <ArticleId IdType="pubmed">27657448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamkwalala A.R., Newhouse P.A. Beyond Acetylcholinesterase Inhibitors: Novel Cholinergic Treatments for Alzheimer’s Disease. Curr. Alzheimer Res. 2017;14:377–392. doi: 10.2174/1567205013666160930112625.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1567205013666160930112625</ArticleId>
            <ArticleId IdType="pubmed">27697062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nyakas C., Granic I., Halmy L.G., Banerjee P., Luiten P.G.M. The Basal Forebrain Cholinergic System in Aging and Dementia. Rescuing Cholinergic Neurons from Neurotoxic Amyloid-Β42 with Memantine. Behav. Brain Res. 2011;221:594–603. doi: 10.1016/j.bbr.2010.05.033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbr.2010.05.033</ArticleId>
            <ArticleId IdType="pubmed">20553766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thiele A. Muscarinic Signaling in the Brain. Ann. Rev. Neurosci. 2013;36:271–294. doi: 10.1146/annurev-neuro-062012-170433.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-neuro-062012-170433</ArticleId>
            <ArticleId IdType="pubmed">23841840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dani J.A., Bertrand D. Nicotinic Acetylcholine Receptors and Nicotinic Cholinergic Mechanisms of the Central Nervous System. Annu. Rev. Pharmacol. Toxicol. 2007;47:699–729. doi: 10.1146/annurev.pharmtox.47.120505.105214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.pharmtox.47.120505.105214</ArticleId>
            <ArticleId IdType="pubmed">17009926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gotti C., Zoli M., Clementi F. Brain Nicotinic Acetylcholine Receptors: Native Subtypes and Their Relevance. Trends Pharmacol. Sci. 2006;27:482–491. doi: 10.1016/j.tips.2006.07.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tips.2006.07.004</ArticleId>
            <ArticleId IdType="pubmed">16876883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J., Ishikawa M., Zhang J., Hashimoto K. Brain Imaging of Nicotinic Receptors in Alzheimer’s Disease.  [(accessed on 13 November 2020)]; doi: 10.4061/2010/548913. Available online:  https://www.hindawi.com/journals/ijad/2010/548913/</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4061/2010/548913</ArticleId>
            <ArticleId IdType="pmc">PMC3022172</ArticleId>
            <ArticleId IdType="pubmed">21253523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teipel S.J., Meindl T., Grinberg L., Grothe M., Cantero J.L., Reiser M.F., Möller H.-J., Heinsen H., Hampel H. The Cholinergic System in Mild Cognitive Impairment and Alzheimer’s Disease: An in Vivo MRI and DTI Study. Hum. Brain Mapp. 2011;32:1349–1362. doi: 10.1002/hbm.21111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hbm.21111</ArticleId>
            <ArticleId IdType="pmc">PMC5899896</ArticleId>
            <ArticleId IdType="pubmed">20672311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Egea J., Buendia I., Parada E., Navarro E., León R., Lopez M.G. Anti-Inflammatory Role of Microglial Alpha7 NAChRs and Its Role in Neuroprotection. Biochem. Pharmacol. 2015;97:463–472. doi: 10.1016/j.bcp.2015.07.032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2015.07.032</ArticleId>
            <ArticleId IdType="pubmed">26232730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabri O., Meyer P.M., Gräf S., Hesse S., Wilke S., Becker G.-A., Rullmann M., Patt M., Luthardt J., Wagenknecht G., et al.  Cognitive Correlates of Α4β2 Nicotinic Acetylcholine Receptors in Mild Alzheimer’s Dementia. Brain. 2018;141:1840–1854. doi: 10.1093/brain/awy099.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awy099</ArticleId>
            <ArticleId IdType="pmc">PMC5972585</ArticleId>
            <ArticleId IdType="pubmed">29672680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guillem K., Bloem B., Poorthuis R.B., Loos M., Smit A.B., Maskos U., Spijker S., Mansvelder H.D. Nicotinic Acetylcholine Receptor Β2 Subunits in the Medial Prefrontal Cortex Control Attention. Science. 2011;333:888–891. doi: 10.1126/science.1207079.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1207079</ArticleId>
            <ArticleId IdType="pubmed">21836018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H.-Y., Lee D.H.S., D’Andrea M.R., Peterson P.A., Shank R.P., Reitz A.B. β-Amyloid1–42 Binds to Α7 Nicotinic Acetylcholine Receptor with High Affinity Implications for Alzheimer’s disease pathology. J. Biol. Chem. 2000;275:5626–5632. doi: 10.1074/jbc.275.8.5626.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.275.8.5626</ArticleId>
            <ArticleId IdType="pubmed">10681545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma K.-G., Qian Y.-H. Alpha 7 Nicotinic Acetylcholine Receptor and Its Effects on Alzheimer’s Disease. Neuropeptides. 2019;73:96–106. doi: 10.1016/j.npep.2018.12.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.npep.2018.12.003</ArticleId>
            <ArticleId IdType="pubmed">30579679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Q., Huang Y., Xue F., Simard A., DeChon J., Li G., Zhang J., Lucero L., Wang M., Sierks M., et al.  A Novel Nicotinic Acetylcholine Receptor Subtype in Basal Forebrain Cholinergic Neurons with High Sensitivity to Amyloid Peptides. J. Neurosci. 2009;29:918–929. doi: 10.1523/JNEUROSCI.3952-08.2009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.3952-08.2009</ArticleId>
            <ArticleId IdType="pmc">PMC2857410</ArticleId>
            <ArticleId IdType="pubmed">19176801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Q., Huang Y., Shen J., Steffensen S., Wu J. Functional Α7β2 Nicotinic Acetylcholine Receptors Expressed in Hippocampal Interneurons Exhibit High Sensitivity to Pathological Level of Amyloid β Peptides. BMC Neurosci. 2012;13:155.  doi: 10.1186/1471-2202-13-155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2202-13-155</ArticleId>
            <ArticleId IdType="pmc">PMC3573893</ArticleId>
            <ArticleId IdType="pubmed">23272676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Picomolar Amyloid-β Positively Modulates Synaptic Plasticity and Memory in Hippocampus | Journal of Neuroscience.  [(accessed on 1 November 2020)]; Available online:  https://www.jneurosci.org/content/28/53/14537.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2673049</ArticleId>
            <ArticleId IdType="pubmed">19118188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Plant L.D., Boyle J.P., Smith I.F., Peers C., Pearson H.A. The Production of Amyloid β Peptide Is a Critical Requirement for the Viability of Central Neurons. J. Neurosci. 2003;23:5531–5535. doi: 10.1523/JNEUROSCI.23-13-05531.2003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.23-13-05531.2003</ArticleId>
            <ArticleId IdType="pmc">PMC6741264</ArticleId>
            <ArticleId IdType="pubmed">12843253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lombardo S., Maskos U. Role of the Nicotinic Acetylcholine Receptor in Alzheimer’s Disease Pathology and Treatment. Neuropharmacology. 2015;96:255–262. doi: 10.1016/j.neuropharm.2014.11.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuropharm.2014.11.018</ArticleId>
            <ArticleId IdType="pubmed">25514383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chu L.W., Ma E.S.K., Lam K.K.Y., Chan M.F., Lee D.H.S. Increased Alpha 7 Nicotinic Acetylcholine Receptor Protein Levels in Alzheimer’s Disease Patients. Dement. Geriatr. Cogn. Disord. 2005;19:106–112. doi: 10.1159/000082661.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000082661</ArticleId>
            <ArticleId IdType="pubmed">15591800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H.-Y., Stucky A., Liu J., Shen C., Trocme-Thibierge C., Morain P. Dissociating Beta-Amyloid from Alpha 7 Nicotinic Acetylcholine Receptor by a Novel Therapeutic Agent, S 24795, Normalizes Alpha 7 Nicotinic Acetylcholine and NMDA Receptor Function in Alzheimer’s Disease Brain. J. Neurosci. 2009;29:10961–10973. doi: 10.1523/JNEUROSCI.6088-08.2009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.6088-08.2009</ArticleId>
            <ArticleId IdType="pmc">PMC6665534</ArticleId>
            <ArticleId IdType="pubmed">19726654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoskin J.L., Al-Hasan Y., Sabbagh M.N. Nicotinic Acetylcholine Receptor Agonists for the Treatment of Alzheimer’s Dementia: An Update. Nicotine Tob. Res. 2018;21:370–376. doi: 10.1093/ntr/nty116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ntr/nty116</ArticleId>
            <ArticleId IdType="pmc">PMC6379052</ArticleId>
            <ArticleId IdType="pubmed">30137524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng Q., Yakel J.L. The Effect of Α7 Nicotinic Receptor Activation on Glutamatergic Transmission in the Hippocampus. Biochem. Pharmacol. 2015;97:439–444. doi: 10.1016/j.bcp.2015.07.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2015.07.015</ArticleId>
            <ArticleId IdType="pmc">PMC4600449</ArticleId>
            <ArticleId IdType="pubmed">26212541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janak P.H., Tye K.M. From Circuits to Behaviour in the Amygdala. Nature. 2015;517:284–292. doi: 10.1038/nature14188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature14188</ArticleId>
            <ArticleId IdType="pmc">PMC4565157</ArticleId>
            <ArticleId IdType="pubmed">25592533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hascup K.N., Hascup E.R. Soluble Amyloid-Β42 Stimulates Glutamate Release through Activation of the Α7 Nicotinic Acetylcholine Receptor. J. Alzheimers Dis. 2016;53:337–347. doi: 10.3233/JAD-160041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/JAD-160041</ArticleId>
            <ArticleId IdType="pubmed">27163813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oddo S., Caccamo A., Green K.N., Liang K., Tran L., Chen Y., Leslie F.M., LaFerla F.M. Chronic Nicotine Administration Exacerbates Tau Pathology in a Transgenic Model of Alzheimer’s Disease. Proc. Natl. Acad. Sci. USA. 2005;102:3046–3051. doi: 10.1073/pnas.0408500102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0408500102</ArticleId>
            <ArticleId IdType="pmc">PMC549455</ArticleId>
            <ArticleId IdType="pubmed">15705720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eyjolfsdottir H., Eriksdotter M., Linderoth B., Lind G., Juliusson B., Kusk P., Almkvist O., Andreasen N., Blennow K., Ferreira D., et al.  Targeted Delivery of Nerve Growth Factor to the Cholinergic Basal Forebrain of Alzheimer’s Disease Patients: Application of a Second-Generation Encapsulated Cell Biodelivery Device. Alzheimers Res. Ther. 2016;8:30. doi: 10.1186/s13195-016-0195-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13195-016-0195-9</ArticleId>
            <ArticleId IdType="pmc">PMC4936020</ArticleId>
            <ArticleId IdType="pubmed">27389402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wallenstein G.V., Vago D.R. Intrahippocampal Scopolamine Impairs Both Acquisition and Consolidation of Contextual Fear Conditioning. Neurobiol. Learn. Memory. 2001;75:245–252. doi: 10.1006/nlme.2001.4005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/nlme.2001.4005</ArticleId>
            <ArticleId IdType="pubmed">11300731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Avila J. Muscarinic Receptors and Alzheimer’s Disease. Neurodegener. Dis. Manag. 2011;1:267–269. doi: 10.2217/nmt.11.43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/nmt.11.43</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang S., Li Y., Zhang C., Zhao Y., Bu G., Xu H., Zhang Y.-W. M1 Muscarinic Acetylcholine Receptor in Alzheimer’s Disease. Neurosci. Bull. 2014;30:295–307. doi: 10.1007/s12264-013-1406-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12264-013-1406-z</ArticleId>
            <ArticleId IdType="pmc">PMC5562652</ArticleId>
            <ArticleId IdType="pubmed">24590577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caccamo A., Oddo S., Billings L.M., Green K.N., Martinez-Coria H., Fisher A., LaFerla F.M. M1 Receptors Play a Central Role in Modulating AD-like Pathology in Transgenic Mice. Neuron. 2006;49:671–682. doi: 10.1016/j.neuron.2006.01.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuron.2006.01.020</ArticleId>
            <ArticleId IdType="pubmed">16504943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Felder C.C., Goldsmith P.J., Jackson K., Sanger H.E., Evans D.A., Mogg A.J., Broad L.M. Current Status of Muscarinic M1 and M4 Receptors as Drug Targets for Neurodegenerative Diseases. Neuropharmacology. 2018;136:449–458. doi: 10.1016/j.neuropharm.2018.01.028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuropharm.2018.01.028</ArticleId>
            <ArticleId IdType="pubmed">29374561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomsen M., Sørensen G., Dencker D. Physiological Roles of CNS Muscarinic Receptors Gained from Knockout Mice. Pt CNeuropharmacology. 2018;136:411–420. doi: 10.1016/j.neuropharm.2017.09.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuropharm.2017.09.011</ArticleId>
            <ArticleId IdType="pmc">PMC5845799</ArticleId>
            <ArticleId IdType="pubmed">28911965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dennis S.H., Pasqui F., Colvin E.M., Sanger H., Mogg A.J., Felder C.C., Broad L.M., Fitzjohn S.M., Isaac J.T.R., Mellor J.R. Activation of Muscarinic M1 Acetylcholine Receptors Induces Long-Term Potentiation in the Hippocampus. Cereb. Cortex. 2016;26:414–426. doi: 10.1093/cercor/bhv227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cercor/bhv227</ArticleId>
            <ArticleId IdType="pmc">PMC4677984</ArticleId>
            <ArticleId IdType="pubmed">26472558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dasari S., Gulledge A.T. M1 and M4 Receptors Modulate Hippocampal Pyramidal Neurons. J. Neurophysiol. 2010;105:779–792. doi: 10.1152/jn.00686.2010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/jn.00686.2010</ArticleId>
            <ArticleId IdType="pmc">PMC3059175</ArticleId>
            <ArticleId IdType="pubmed">21160001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gulledge A.T., Bucci D.J., Zhang S.S., Matsui M., Yeh H.H. M1 Receptors Mediate Cholinergic Modulation of Excitability in Neocortical Pyramidal Neurons. J. Neurosci. 2009;29:9888–9902. doi: 10.1523/JNEUROSCI.1366-09.2009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.1366-09.2009</ArticleId>
            <ArticleId IdType="pmc">PMC2745329</ArticleId>
            <ArticleId IdType="pubmed">19657040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Medeiros R., Kitazawa M., Caccamo A., Baglietto-Vargas D., Estrada-Hernandez T., Cribbs D.H., Fisher A., LaFerla F.M. Loss of Muscarinic M1 Receptor Exacerbates Alzheimer’s Disease–Like Pathology and Cognitive Decline. Am. J. Pathol. 2011;179:980–991. doi: 10.1016/j.ajpath.2011.04.041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajpath.2011.04.041</ArticleId>
            <ArticleId IdType="pmc">PMC3157199</ArticleId>
            <ArticleId IdType="pubmed">21704011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Development of M1 mAChR Allosteric and Bitopic Ligands: Prospective Therapeutics for the Treatment of Cognitive Deficits | ACS Chemical Neuroscience.  [(accessed on 11 November 2020)]; Available online:  https://pubs.acs.org/doi/10.1021/cn400086m.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/cn400086m</ArticleId>
            <ArticleId IdType="pmc">PMC3715844</ArticleId>
            <ArticleId IdType="pubmed">23659787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bainbridge N.K., Koselke L.R., Jeon J., Bailey K.R., Wess J., Crawley J.N., Wrenn C.C. Learning and Memory Impairments in a Congenic C57BL/6 Strain of Mice That Lacks the M2 Muscarinic Acetylcholine Receptor Subtype. Behav. Brain Res. 2008;190:50–58. doi: 10.1016/j.bbr.2008.02.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbr.2008.02.001</ArticleId>
            <ArticleId IdType="pmc">PMC2696485</ArticleId>
            <ArticleId IdType="pubmed">18346798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hagena H., Hansen N., Manahan-Vaughan D. β-Adrenergic Control of Hippocampal Function: Subserving the Choreography of Synaptic Information Storage and Memory. Cereb. Cortex. 2016;26:1349–1364. doi: 10.1093/cercor/bhv330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cercor/bhv330</ArticleId>
            <ArticleId IdType="pmc">PMC4785955</ArticleId>
            <ArticleId IdType="pubmed">26804338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hansen N., Manahan-Vaughan D. Hippocampal Long-Term Potentiation That Is Elicited by Perforant Path Stimulation or That Occurs in Conjunction with Spatial Learning Is Tightly Controlled by Beta-Adrenoreceptors and the Locus Coeruleus. Hippocampus. 2015;25:1285–1298. doi: 10.1002/hipo.22436.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hipo.22436</ArticleId>
            <ArticleId IdType="pmc">PMC6680149</ArticleId>
            <ArticleId IdType="pubmed">25727388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song S., Jiang L., Oyarzabal E.A., Wilson B., Li Z., Shih Y.-Y.I., Wang Q., Hong J.-S. Loss of Brain Norepinephrine Elicits Neuroinflammation-Mediated Oxidative Injury and Selective Caudo-Rostral Neurodegeneration. Mol. Neurobiol. 2019;56:2653–2669. doi: 10.1007/s12035-018-1235-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12035-018-1235-1</ArticleId>
            <ArticleId IdType="pmc">PMC6348128</ArticleId>
            <ArticleId IdType="pubmed">30051353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leanza G., Gulino R., Zorec R. Noradrenergic Hypothesis Linking Neurodegeneration-Based Cognitive Decline and Astroglia. Front. Mol. Neurosci. 2018;11 doi: 10.3389/fnmol.2018.00254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnmol.2018.00254</ArticleId>
            <ArticleId IdType="pmc">PMC6072880</ArticleId>
            <ArticleId IdType="pubmed">30100866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borodovitsyna O., Flamini M., Chandler D. Noradrenergic Modulation of Cognition in Health and Disease. Neural Plast. 2017;2017 doi: 10.1155/2017/6031478.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2017/6031478</ArticleId>
            <ArticleId IdType="pmc">PMC5450174</ArticleId>
            <ArticleId IdType="pubmed">28596922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinshenker D. Functional Consequences of Locus Coeruleus Degeneration in Alzheimer’s Disease. Curr. Alzheimer Res. 2008;5:342–345. doi: 10.2174/156720508784533286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/156720508784533286</ArticleId>
            <ArticleId IdType="pubmed">18537547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hammerschmidt T., Kummer M.P., Terwel D., Martinez A., Gorji A., Pape H.-C., Rommelfanger K.S., Schroeder J.P., Stoll M., Schultze J., et al.  Selective Loss of Noradrenaline Exacerbates Early Cognitive Dysfunction and Synaptic Deficits in APP/PS1 Mice. Biol. Psychiatry. 2013;73:454–463. doi: 10.1016/j.biopsych.2012.06.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopsych.2012.06.013</ArticleId>
            <ArticleId IdType="pmc">PMC4712953</ArticleId>
            <ArticleId IdType="pubmed">22883210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perez D.M. Α1-Adrenergic Receptors in Neurotransmission, Synaptic Plasticity, and Cognition. Front. Pharmacol. 2020;11 doi: 10.3389/fphar.2020.581098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2020.581098</ArticleId>
            <ArticleId IdType="pmc">PMC7553051</ArticleId>
            <ArticleId IdType="pubmed">33117176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Betts M.J., Kirilina E., Otaduy M.C.G., Ivanov D., Acosta-Cabronero J., Callaghan M.F., Lambert C., Cardenas-Blanco A., Pine K., Passamonti L., et al.  Locus Coeruleus Imaging as a Biomarker for Noradrenergic Dysfunction in Neurodegenerative Diseases. Brain. 2019;142:2558–2571. doi: 10.1093/brain/awz193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awz193</ArticleId>
            <ArticleId IdType="pmc">PMC6736046</ArticleId>
            <ArticleId IdType="pubmed">31327002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grudzien A., Shaw P., Weintraub S., Bigio E., Mash D.C., Mesulam M.M. Locus Coeruleus Neurofibrillary Degeneration in Aging, Mild Cognitive Impairment and Early Alzheimer’s Disease. Neurobiol. Aging. 2007;28:327–335. doi: 10.1016/j.neurobiolaging.2006.02.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neurobiolaging.2006.02.007</ArticleId>
            <ArticleId IdType="pubmed">16574280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Theofilas P., Dunlop S., Heinsen H., Grinberg L.T. Turning on the Light Within: Subcortical Nuclei of the Isodentritic Core and Their Role in Alzheimer’s Disease Pathogenesis. J. Alzheimers Dis. 2015;46:17–34. doi: 10.3233/JAD-142682.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/JAD-142682</ArticleId>
            <ArticleId IdType="pmc">PMC4550582</ArticleId>
            <ArticleId IdType="pubmed">25720408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arendt T., Brückner M.K., Morawski M., Jäger C., Gertz H.-J. Early Neurone Loss in Alzheimer’s Disease: Cortical or Subcortical? Acta Neuropathol. Commun. 2015;3:10. doi: 10.1186/s40478-015-0187-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40478-015-0187-1</ArticleId>
            <ArticleId IdType="pmc">PMC4359478</ArticleId>
            <ArticleId IdType="pubmed">25853173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan-Palay V., Asan E. Alterations in Catecholamine Neurons of the Locus Coeruleus in Senile Dementia of the Alzheimer Type and in Parkinson’s Disease with and without Dementia and Depression. J. Comp. Neurol. 1989;287:373–392. doi: 10.1002/cne.902870308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cne.902870308</ArticleId>
            <ArticleId IdType="pubmed">2570794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson R.S., Boyle P.A., Yu L., Barnes L.L., Schneider J.A., Bennett D.A. Life-Span Cognitive Activity, Neuropathologic Burden, and Cognitive Aging. Neurology. 2013;81:314–321. doi: 10.1212/WNL.0b013e31829c5e8a.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e31829c5e8a</ArticleId>
            <ArticleId IdType="pmc">PMC3772831</ArticleId>
            <ArticleId IdType="pubmed">23825173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szot P., White S.S., Greenup J.L., Leverenz J.B., Peskind E.R., Raskind M.A. Compensatory Changes in the Noradrenergic Nervous System in the Locus Ceruleus and Hippocampus of Postmortem Subjects with Alzheimer’s Disease and Dementia with Lewy Bodies. J. Neurosci. 2006;26:467–478. doi: 10.1523/JNEUROSCI.4265-05.2006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.4265-05.2006</ArticleId>
            <ArticleId IdType="pmc">PMC6674412</ArticleId>
            <ArticleId IdType="pubmed">16407544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taylor T.N., Alter S.P., Wang M., Goldstein D.S., Miller G.W. Reduced Vesicular Storage of Catecholamines Causes Progressive Degeneration in the Locus Ceruleus. Neuropharmacology. 2014;76:97–105. doi: 10.1016/j.neuropharm.2013.08.033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuropharm.2013.08.033</ArticleId>
            <ArticleId IdType="pmc">PMC4049095</ArticleId>
            <ArticleId IdType="pubmed">24025942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McMillan P.J., White S.S., Franklin A., Greenup J.L., Leverenz J.B., Raskind M.A., Szot P. Differential Response of the Central Noradrenergic Nervous System to the Loss of Locus Coeruleus Neurons in Parkinson’s Disease and Alzheimer’s Disease. Brain Res. 2011;1373:240–252. doi: 10.1016/j.brainres.2010.12.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.brainres.2010.12.015</ArticleId>
            <ArticleId IdType="pmc">PMC3038670</ArticleId>
            <ArticleId IdType="pubmed">21147074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szabadi E. Functional Neuroanatomy of the Central Noradrenergic System. J. Psychopharmacol. 2013;27:659–693. doi: 10.1177/0269881113490326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0269881113490326</ArticleId>
            <ArticleId IdType="pubmed">23761387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zweig R.M., Ross C.A., Hedreen J.C., Steele C., Cardillo J.E., Whitehouse P.J., Folstein M.F., Price D.L. Neuropathology of Aminergic Nuclei in Alzheimer’s Disease. Progress Clin. Biol. Res. 1989;317:353–365. doi: 10.1002/ana.410240210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410240210</ArticleId>
            <ArticleId IdType="pubmed">2602423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mustapic M., Presecki P., Pivac N., Mimica N., Hof P.R., Simic G., Folnegovic-Smalc V., Muck-Seler D. Genotype-Independent Decrease in Plasma Dopamine Beta-Hydroxylase Activity in Alzheimer’s Disease. Progress Neuro-Psychopharmacol. Biol. Psychiatry. 2013;44:94–99. doi: 10.1016/j.pnpbp.2013.02.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pnpbp.2013.02.002</ArticleId>
            <ArticleId IdType="pmc">PMC3952071</ArticleId>
            <ArticleId IdType="pubmed">23416088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stefani A., Olivola E., Liguori C., Hainsworth A.H., Saviozzi V., Angileri G., D’Angelo V., Galati S., Pierantozzi M. Catecholamine-Based Treatment in AD Patients: Expectations and Delusions. Front. Aging Neurosci. 2015;7:67. doi: 10.3389/fnagi.2015.00067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnagi.2015.00067</ArticleId>
            <ArticleId IdType="pmc">PMC4418272</ArticleId>
            <ArticleId IdType="pubmed">25999852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guzmán-Ramos K., Moreno-Castilla P., Castro-Cruz M., McGaugh J.L., Martínez-Coria H., LaFerla F.M., Bermúdez-Rattoni F. Restoration of Dopamine Release Deficits during Object Recognition Memory Acquisition Attenuates Cognitive Impairment in a Triple Transgenic Mice Model of Alzheimer’s Disease. Learn. Mem. 2012;19:453–460. doi: 10.1101/lm.026070.112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/lm.026070.112</ArticleId>
            <ArticleId IdType="pubmed">22984283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perkovic M.N., Strac D.S., Tudor L., Konjevod M., Erjavec G.N., Pivac N. Catechol-O-Methyltransferase, Cognition and Alzheimer’s Disease. Curr. Alzheimer Res. 2018;15:408–419. doi: 10.2174/1567205015666171212094229.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1567205015666171212094229</ArticleId>
            <ArticleId IdType="pubmed">29231139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gannon M., Wang Q. Complex Noradrenergic Dysfunction in Alzheimer’s Disease: Low Norepinephrine Input Is Not Always to Blame. Brain Res. 2019;1702:12–16. doi: 10.1016/j.brainres.2018.01.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.brainres.2018.01.001</ArticleId>
            <ArticleId IdType="pmc">PMC6855395</ArticleId>
            <ArticleId IdType="pubmed">29307592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McBurney-Lin J., Lu J., Zuo Y., Yang H. Locus Coeruleus-Norepinephrine Modulation of Sensory Processing and Perception: A Focused Review. Neurosci. Biobehav. Rev. 2019;105:190–199. doi: 10.1016/j.neubiorev.2019.06.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neubiorev.2019.06.009</ArticleId>
            <ArticleId IdType="pmc">PMC6742544</ArticleId>
            <ArticleId IdType="pubmed">31260703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gannon M., Che P., Chen Y., Jiao K., Roberson E.D., Wang Q. Noradrenergic Dysfunction in Alzheimer’s Disease. Front. Neurosci. 2015;9 doi: 10.3389/fnins.2015.00220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnins.2015.00220</ArticleId>
            <ArticleId IdType="pmc">PMC4469831</ArticleId>
            <ArticleId IdType="pubmed">26136654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leverenz J.B., Miller M.A., Dobie D.J., Peskind E.R., Raskind M.A. Increased Alpha 2-Adrenergic Receptor Binding in Locus Coeruleus Projection Areas in Dementia with Lewy Bodies. Neurobiol. Aging. 2001;22:555–561. doi: 10.1016/S0197-4580(01)00221-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0197-4580(01)00221-4</ArticleId>
            <ArticleId IdType="pubmed">11445255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hashimoto E., Ozawa H., Saito T., Gsell W., Takahata N., Riederer P., Frölich L. Impairment of G(Salpha) Function in Human Brain Cortex of Alzheimer’s Disease: Comparison with Normal Aging. J. Neural Transm. 2004;111:311–322. doi: 10.1007/s00702-003-0089-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00702-003-0089-4</ArticleId>
            <ArticleId IdType="pubmed">14991457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamoto-Sasaki M., Ozawa H., Saito T., Rösler M., Riederer P. Impaired Phosphorylation of Cyclic AMP Response Element Binding Protein in the Hippocampus of Dementia of the Alzheimer Type. Brain Res. 1999;824:300–303. doi: 10.1016/S0006-8993(99)01220-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0006-8993(99)01220-2</ArticleId>
            <ArticleId IdType="pubmed">10196463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cowburn R.F., O’Neill C., Bonkale W.L., Ohm T.G., Fastbom J. Receptor-G-Protein Signalling in Alzheimer’s Disease. Biochem. Soc. Symp. 2001;67:163–175. doi: 10.1042/bst028a017c.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/bst028a017c</ArticleId>
            <ArticleId IdType="pubmed">11447833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dyer-Reaves K., Goodman A.M., Nelson A.R., McMahon L.L. Alpha1-Adrenergic Receptor Mediated Long-Term Depression at CA3-CA1 Synapses Can Be Induced via Accumulation of Endogenous Norepinephrine and Is Preserved Following Noradrenergic Denervation. Front. Synaptic Neurosci. 2019;11 doi: 10.3389/fnsyn.2019.00027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnsyn.2019.00027</ArticleId>
            <ArticleId IdType="pmc">PMC6794465</ArticleId>
            <ArticleId IdType="pubmed">31649525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katsouri L., Vizcaychipi M.P., McArthur S., Harrison I., Suárez-Calvet M., Lleo A., Lloyd D.G., Ma D., Sastre M. Prazosin, an α(1)-Adrenoceptor Antagonist, Prevents Memory Deterioration in the APP23 Transgenic Mouse Model of Alzheimer’s Disease. Neurobiol. Aging. 2013;34:1105–1115. doi: 10.1016/j.neurobiolaging.2012.09.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.09.010</ArticleId>
            <ArticleId IdType="pubmed">23063647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thathiah A., De Strooper B. The Role of G Protein-Coupled Receptors in the Pathology of Alzheimer’s Disease. Nat. Rev. Neurosci. 2011;12:73–87. doi: 10.1038/nrn2977.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrn2977</ArticleId>
            <ArticleId IdType="pubmed">21248787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang D., Fu Q., Zhou Y., Xu B., Shi Q., Igwe B., Matt L., Hell J.W., Wisely E.V., Oddo S., et al.  Β2 Adrenergic Receptor, Protein Kinase A (PKA) and c-Jun N-Terminal Kinase (JNK) Signaling Pathways Mediate Tau Pathology in Alzheimer Disease Models. J. Biol. Chem. 2013;288:10298–10307. doi: 10.1074/jbc.M112.415141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M112.415141</ArticleId>
            <ArticleId IdType="pmc">PMC3624413</ArticleId>
            <ArticleId IdType="pubmed">23430246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang D., Yuen E.Y., Zhou Y., Yan Z., Xiang Y.K. Amyloid β Peptide-(1–42) Induces Internalization and Degradation of Β2 Adrenergic Receptors in Prefrontal Cortical Neurons. J. Biol. Chem. 2011;286:31852–31863. doi: 10.1074/jbc.M111.244335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M111.244335</ArticleId>
            <ArticleId IdType="pmc">PMC3173113</ArticleId>
            <ArticleId IdType="pubmed">21757762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y., Peng Y., Che P., Gannon M., Liu Y., Li L., Bu G., van Groen T., Jiao K., Wang Q. Α2A Adrenergic Receptor Promotes Amyloidogenesis through Disrupting APP-SorLA Interaction. Proc. Natl. Acad. Sci. USA. 2014;111:17296–17301. doi: 10.1073/pnas.1409513111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1409513111</ArticleId>
            <ArticleId IdType="pmc">PMC4260556</ArticleId>
            <ArticleId IdType="pubmed">25404298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coradazzi M., Gulino R., Fieramosca F., Falzacappa L.V., Riggi M., Leanza G. Selective Noradrenaline Depletion Impairs Working Memory and Hippocampal Neurogenesis. Neurobiol. Aging. 2016;48:93–102. doi: 10.1016/j.neurobiolaging.2016.08.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neurobiolaging.2016.08.012</ArticleId>
            <ArticleId IdType="pubmed">27644078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murchison C.F., Schutsky K., Jin S.-H., Thomas S.A. Norepinephrine and SS₁-Adrenergic Signaling Facilitate Activation of Hippocampal CA1 Pyramidal Neurons during Contextual Memory Retrieval. Neuroscience. 2011;181:109–116. doi: 10.1016/j.neuroscience.2011.02.049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuroscience.2011.02.049</ArticleId>
            <ArticleId IdType="pmc">PMC3074031</ArticleId>
            <ArticleId IdType="pubmed">21377513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ouyang M., Young M.B., Lestini M.M., Schutsky K., Thomas S.A. Redundant Catecholamine Signaling Consolidates Fear Memory via Phospholipase C. J. Neurosci. 2012;32:1932–1941. doi: 10.1523/JNEUROSCI.5231-11.2012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.5231-11.2012</ArticleId>
            <ArticleId IdType="pmc">PMC3306178</ArticleId>
            <ArticleId IdType="pubmed">22323706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L., Ouyang M., Ganellin C.R., Thomas S.A. The Slow Afterhyperpolarization: A Target of Β1-Adrenergic Signaling in Hippocampus-Dependent Memory Retrieval. J. Neurosci. 2013;33:5006–5016. doi: 10.1523/JNEUROSCI.3834-12.2013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.3834-12.2013</ArticleId>
            <ArticleId IdType="pmc">PMC3632069</ArticleId>
            <ArticleId IdType="pubmed">23486971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evans A.K., Ardestani P.M., Yi B., Park H.H., Lam R.K., Shamloo M. Beta-Adrenergic Receptor Antagonism Is Proinflammatory and Exacerbates Neuroinflammation in a Mouse Model of Alzheimer’s Disease. Neurobiol. Dis. 2020;146:105089. doi: 10.1016/j.nbd.2020.105089.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nbd.2020.105089</ArticleId>
            <ArticleId IdType="pmc">PMC7686098</ArticleId>
            <ArticleId IdType="pubmed">32971233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kelly S.C., He B., Perez S.E., Ginsberg S.D., Mufson E.J., Counts S.E. Locus Coeruleus Cellular and Molecular Pathology during the Progression of Alzheimer’s Disease. Acta Neuropathol. Commun. 2017;5 doi: 10.1186/s40478-017-0411-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40478-017-0411-2</ArticleId>
            <ArticleId IdType="pmc">PMC5251221</ArticleId>
            <ArticleId IdType="pubmed">28109312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grundke-Iqbal I., Iqbal K., Tung Y.C., Quinlan M., Wisniewski H.M., Binder L.I. Abnormal Phosphorylation of the Microtubule-Associated Protein Tau (Tau) in Alzheimer Cytoskeletal Pathology. Proc. Natl. Acad. Sci. USA. 1986;83:4913–4917. doi: 10.1073/pnas.83.13.4913.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.83.13.4913</ArticleId>
            <ArticleId IdType="pmc">PMC323854</ArticleId>
            <ArticleId IdType="pubmed">3088567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iba M., McBride J.D., Guo J.L., Zhang B., Trojanowski J.Q., Lee V.M.-Y. Tau Pathology Spread in PS19 Tau Transgenic Mice Following Locus Coeruleus (LC) Injections of Synthetic Tau Fibrils Is Determined by the LC’s Afferent and Efferent Connections. Acta Neuropathol. 2015;130:349–362. doi: 10.1007/s00401-015-1458-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-015-1458-4</ArticleId>
            <ArticleId IdType="pmc">PMC4545685</ArticleId>
            <ArticleId IdType="pubmed">26150341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kummer M.P., Hammerschmidt T., Martinez A., Terwel D., Eichele G., Witten A., Figura S., Stoll M., Schwartz S., Pape H.-C., et al.  Ear2 Deletion Causes Early Memory and Learning Deficits in APP/PS1 Mice. J. Neurosci. 2014;34:8845–8854. doi: 10.1523/JNEUROSCI.4027-13.2014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.4027-13.2014</ArticleId>
            <ArticleId IdType="pmc">PMC4147626</ArticleId>
            <ArticleId IdType="pubmed">24966384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hansen N. The Longevity of Hippocampus-Dependent Memory Is Orchestrated by the Locus Coeruleus-Noradrenergic System. Neural Plast. 2017;2017 doi: 10.1155/2017/2727602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2017/2727602</ArticleId>
            <ArticleId IdType="pmc">PMC5485371</ArticleId>
            <ArticleId IdType="pubmed">28695015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao J., Hou J., Ping J., Cai D. Advances in Developing Novel Therapeutic Strategies for Alzheimer’s Disease. Mol. Neurodegener. 2018;13 doi: 10.1186/s13024-018-0299-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13024-018-0299-8</ArticleId>
            <ArticleId IdType="pmc">PMC6291983</ArticleId>
            <ArticleId IdType="pubmed">30541602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maity S., Jarome T.J., Blair J., Lubin F.D., Nguyen P.V. Noradrenaline Goes Nuclear: Epigenetic Modifications during Long-Lasting Synaptic Potentiation Triggered by Activation of β-Adrenergic Receptors. J. Physiol. 2016;594:863–881. doi: 10.1113/JP271432.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1113/JP271432</ArticleId>
            <ArticleId IdType="pmc">PMC4753274</ArticleId>
            <ArticleId IdType="pubmed">26574176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lonze B.E., Ginty D.D. Function and Regulation of CREB Family Transcription Factors in the Nervous System. Neuron. 2002;35:605–623. doi: 10.1016/S0896-6273(02)00828-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0896-6273(02)00828-0</ArticleId>
            <ArticleId IdType="pubmed">12194863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Epigenetics of Brain Disorders: The Paradigm of Alzheimer’s Disease | OMICS International.  [(accessed on 17 January 2021)]; Available online:  https://www.omicsonline.org/open-access/epigenetics-of-brain-disorders-the-paradigm-of-alzheimer-s-disease-2161-0460-1000229.php?aid=72455&amp;view=mobile.</Citation>
        </Reference>
        <Reference>
          <Citation>Meyer P.-F., Pichet Binette A., Gonneaud J., Breitner J.C.S., Villeneuve S. Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography. JAMA Neurol. 2020;77:508. doi: 10.1001/jamaneurol.2019.4749.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2019.4749</ArticleId>
            <ArticleId IdType="pmc">PMC6990861</ArticleId>
            <ArticleId IdType="pubmed">31961372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zetterberg H., Bendlin B.B. Biomarkers for Alzheimer’s Disease—Preparing for a New Era of Disease-Modifying Therapies. Mol. Psychiatry. 2020:1–13. doi: 10.1038/s41380-020-0721-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41380-020-0721-9</ArticleId>
            <ArticleId IdType="pubmed">32251378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khoury R., Ghossoub E. Diagnostic Biomarkers of Alzheimer’s Disease: A State-of-the-Art Review. Biomark. Neuropsychiatry. 2019;1:100005. doi: 10.1016/j.bionps.2019.100005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bionps.2019.100005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puranik N., Yadav D., Yadav S.K., Chavda V.K., Jin J.-O. Proteomics and Neurodegenerative Disorders: Advancements in the Diagnostic Analysis. Curr. Protein Pept. Sci. 2020 doi: 10.2174/1389203721666200511094222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1389203721666200511094222</ArticleId>
            <ArticleId IdType="pubmed">32392110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lashley T., Schott J.M., Weston P., Murray C.E., Wellington H., Keshavan A., Foti S.C., Foiani M., Toombs J., Rohrer J.D., et al.  Molecular Biomarkers of Alzheimer’s Disease: Progress and Prospects. Dis. Model Mech. 2018;11 doi: 10.1242/dmm.031781.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/dmm.031781</ArticleId>
            <ArticleId IdType="pmc">PMC5992610</ArticleId>
            <ArticleId IdType="pubmed">29739861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lao K., Ji N., Zhang X., Qiao W., Tang Z., Gou X. Drug Development for Alzheimer’s Disease: Review. J. Drug Target. 2019;27:164–173. doi: 10.1080/1061186X.2018.1474361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/1061186X.2018.1474361</ArticleId>
            <ArticleId IdType="pubmed">29732929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verma S., Kumar A., Tripathi T., Kumar A. Muscarinic and Nicotinic Acetylcholine Receptor Agonists: Current Scenario in Alzheimer’s Disease Therapy. J. Pharm. Pharmacol. 2018;70:985–993. doi: 10.1111/jphp.12919.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jphp.12919</ArticleId>
            <ArticleId IdType="pubmed">29663387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Femminella G.D., Rengo G., Pagano G., de Lucia C., Komici K., Parisi V., Cannavo A., Liccardo D., Vigorito C., Filardi P.P., et al.  β-Adrenergic Receptors and G Protein-Coupled Receptor Kinase-2 in Alzheimer’s Disease: A New Paradigm for Prognosis and Therapy? J. Alzheimers Dis. 2013;34:341–347. doi: 10.3233/JAD-121813.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/JAD-121813</ArticleId>
            <ArticleId IdType="pubmed">23207488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu J.-T., Wang N.-D., Ma T., Jiang H., Guan J., Tan L. Roles of β-Adrenergic Receptors in Alzheimer’s Disease: Implications for Novel Therapeutics. Brain Res. Bull. 2011;84:111–117. doi: 10.1016/j.brainresbull.2010.11.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.brainresbull.2010.11.004</ArticleId>
            <ArticleId IdType="pubmed">21129453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang L.-K., Chao S.-P., Hu C.-J. Clinical Trials of New Drugs for Alzheimer Disease. J. Biomed. Sci. 2020;27 doi: 10.1186/s12929-019-0609-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12929-019-0609-7</ArticleId>
            <ArticleId IdType="pmc">PMC6943903</ArticleId>
            <ArticleId IdType="pubmed">31906949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J., Yu J.-T., Tan M.-S., Jiang T., Tan L. Epigenetic Mechanisms in Alzheimer’s Disease: Implications for Pathogenesis and Therapy. Ageing Res. Rev. 2013;12:1024–1041. doi: 10.1016/j.arr.2013.05.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.arr.2013.05.003</ArticleId>
            <ArticleId IdType="pubmed">23688931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coppieters N., Dragunow M. Epigenetics in Alzheimer’s Disease: A Focus on DNA Modifications. Curr. Pharm. Des. 2011;17:3398–3412. doi: 10.2174/138161211798072544.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/138161211798072544</ArticleId>
            <ArticleId IdType="pubmed">21902668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chouliaras L., Rutten B.P.F., Kenis G., Peerbooms O., Visser P.J., Verhey F., van Os J., Steinbusch H.W.M., van den Hove D.L.A. Epigenetic Regulation in the Pathophysiology of Alzheimer’s Disease. Progress Neurobiol. 2010;90:498–510. doi: 10.1016/j.pneurobio.2010.01.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pneurobio.2010.01.002</ArticleId>
            <ArticleId IdType="pubmed">20097254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sezgin Z., Dincer Y. Alzheimer’s Disease and Epigenetic Diet. Neurochem. Int. 2014;78:105–116. doi: 10.1016/j.neuint.2014.09.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuint.2014.09.012</ArticleId>
            <ArticleId IdType="pubmed">25290336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hwang J.-Y., Aromolaran K.A., Zukin R.S. The Emerging Field of Epigenetics in Neurodegeneration and Neuroprotection. Nat. Rev. Neurosci. 2017;18:347–361. doi: 10.1038/nrn.2017.46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrn.2017.46</ArticleId>
            <ArticleId IdType="pmc">PMC6380351</ArticleId>
            <ArticleId IdType="pubmed">28515491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li K., Wei Q., Liu F.-F., Hu F., Xie A.-J., Zhu L.-Q., Liu D. Synaptic Dysfunction in Alzheimer’s Disease: Aβ, Tau, and Epigenetic Alterations. Mol. Neurobiol. 2018;55:3021–3032. doi: 10.1007/s12035-017-0533-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12035-017-0533-3</ArticleId>
            <ArticleId IdType="pubmed">28456942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prasad G.R., Jho E.H. A Concise Review of Human Brain Methylome during Aging and Neurodegenerative Diseases. BMB Rep. 2019;52:577–588. doi: 10.5483/BMBRep.2019.52.10.215.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5483/BMBRep.2019.52.10.215</ArticleId>
            <ArticleId IdType="pmc">PMC6827576</ArticleId>
            <ArticleId IdType="pubmed">31462381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Jager P.L., Srivastava G., Lunnon K., Burgess J., Schalkwyk L.C., Yu L., Eaton M.L., Keenan B.T., Ernst J., McCabe C., et al.  Alzheimer’s Disease: Early Alterations in Brain DNA Methylation at ANK1, BIN1, RHBDF2 and Other Loci. Nat. Neurosci. 2014;17:1156–1163. doi: 10.1038/nn.3786.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nn.3786</ArticleId>
            <ArticleId IdType="pmc">PMC4292795</ArticleId>
            <ArticleId IdType="pubmed">25129075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>West R.L., Lee J.M., Maroun L.E. Hypomethylation of the Amyloid Precursor Protein Gene in the Brain of an Alzheimer’s Disease Patient. J. Mol. Neurosci. 1995;6:141–146. doi: 10.1007/BF02736773.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF02736773</ArticleId>
            <ArticleId IdType="pubmed">8746452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bakulski K.M., Dolinoy D.C., Sartor M.A., Paulson H.L., Konen J.R., Lieberman A.P., Albin R.L., Hu H., Rozek L.S. Genome-Wide DNA Methylation Differences Between Late-Onset Alzheimer’s Disease and Cognitively Normal Controls in Human Frontal Cortex. J. Alzheimers Dis. 2012;29:571–588. doi: 10.3233/JAD-2012-111223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/JAD-2012-111223</ArticleId>
            <ArticleId IdType="pmc">PMC3652332</ArticleId>
            <ArticleId IdType="pubmed">22451312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang K., Schrag M., Crofton A., Trivedi R., Vinters H., Kirsch W. Targeted Proteomics for Quantification of Histone Acetylation in Alzheimer’s Disease. Proteomics. 2012;12:1261–1268. doi: 10.1002/pmic.201200010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pmic.201200010</ArticleId>
            <ArticleId IdType="pmc">PMC6812507</ArticleId>
            <ArticleId IdType="pubmed">22577027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mastroeni D., Delvaux E., Nolz J., Tan Y., Grover A., Oddo S., Coleman P.D. Aberrant Intracellular Localization of H3k4me3 Demonstrates an Early Epigenetic Phenomenon in Alzheimer’s Disease. Neurobiol. Aging. 2015;36:3121–3129. doi: 10.1016/j.neurobiolaging.2015.08.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.08.017</ArticleId>
            <ArticleId IdType="pmc">PMC4838454</ArticleId>
            <ArticleId IdType="pubmed">26553823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Francesco A., Arosio B., Falconi A., Micioni Di Bonaventura M.V., Karimi M., Mari D., Casati M., Maccarrone M., D’Addario C. Global Changes in DNA Methylation in Alzheimer’s Disease Peripheral Blood Mononuclear Cells. Brain Behav. Immun. 2015;45:139–144. doi: 10.1016/j.bbi.2014.11.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbi.2014.11.002</ArticleId>
            <ArticleId IdType="pubmed">25452147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lardenoije R., Roubroeks J.A.Y., Pishva E., Leber M., Wagner H., Iatrou A., Smith A.R., Smith R.G., Eijssen L.M.T., Kleineidam L., et al.  Alzheimer’s Disease-Associated (Hydroxy)Methylomic Changes in the Brain and Blood. Clin. Epigenetics. 2019;11 doi: 10.1186/s13148-019-0755-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13148-019-0755-5</ArticleId>
            <ArticleId IdType="pmc">PMC6880587</ArticleId>
            <ArticleId IdType="pubmed">31775875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mazurek M.F., Beal M.F., Bird E.D., Martin J.B. Oxytocin in Alzheimer’s Disease: Postmortem Brain Levels. Neurology. 1987;37:1001–1003. doi: 10.1212/WNL.37.6.1001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.37.6.1001</ArticleId>
            <ArticleId IdType="pubmed">3587615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mann D.M., Yates P.O., Marcyniuk B. Changes in Alzheimer’s Disease in the Magnocellular Neurones of the Supraoptic and Paraventricular Nuclei of the Hypothalamus and Their Relationship to the Noradrenergic Deficit. Clin. Neuropathol. 1985;4:127–134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3160517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cummings J., Scheltens P., McKeith I., Blesa R., Harrison J.E., Bertolucci P.H.F., Rockwood K., Wilkinson D., Wijker W., Bennett D.A., et al.  Effect Size Analyses of Souvenaid in Patients with Alzheimer’s Disease. J. Alzheimers Dis. 2017;55:1131–1139. doi: 10.3233/JAD-160745.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/JAD-160745</ArticleId>
            <ArticleId IdType="pmc">PMC5147481</ArticleId>
            <ArticleId IdType="pubmed">27767993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scheltens P., Twisk J.W.R., Blesa R., Scarpini E., von Arnim C.A.F., Bongers A., Harrison J., Swinkels S.H.N., Stam C.J., de Waal H., et al.  Efficacy of Souvenaid in Mild Alzheimer’s Disease: Results from a Randomized, Controlled Trial. J. Alzheimers Dis. 2012;31:225–236. doi: 10.3233/JAD-2012-121189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/JAD-2012-121189</ArticleId>
            <ArticleId IdType="pubmed">22766770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Waal H., Stam C.J., Lansbergen M.M., Wieggers R.L., Kamphuis P.J.G.H., Scheltens P., Maestú F., van Straaten E.C.W. The Effect of Souvenaid on Functional Brain Network Organisation in Patients with Mild Alzheimer’s Disease: A Randomised Controlled Study. PLoS ONE. 2014;9:e86558.  doi: 10.1371/journal.pone.0086558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0086558</ArticleId>
            <ArticleId IdType="pmc">PMC3903587</ArticleId>
            <ArticleId IdType="pubmed">24475144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Wijk N., Broersen L.M., de Wilde M.C., Hageman R.J.J., Groenendijk M., Sijben J.W.C., Kamphuis P.J.G.H. Targeting Synaptic Dysfunction in Alzheimer’s Disease by Administering a Specific Nutrient Combination. J. Alzheimers Dis. 2014;38:459–479. doi: 10.3233/JAD-130998.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/JAD-130998</ArticleId>
            <ArticleId IdType="pubmed">23985420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bekdash R.A. Neuroprotective Effects of Choline and Other Methyl Donors. Nutrients. 2019;11:2995.  doi: 10.3390/nu11122995.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/nu11122995</ArticleId>
            <ArticleId IdType="pmc">PMC6950346</ArticleId>
            <ArticleId IdType="pubmed">31817768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muñoz Fernández S.S., Lima Ribeiro S.M. Nutrition and Alzheimer Disease. Clin. Geriatr. Med. 2018;34:677–697. doi: 10.1016/j.cger.2018.06.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cger.2018.06.012</ArticleId>
            <ArticleId IdType="pubmed">30336995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Athanasopoulos D., Karagiannis G., Tsolaki M. Recent Findings in Alzheimer Disease and Nutrition Focusing on Epigenetics. Adv. Nutr. 2016;7:917–927. doi: 10.3945/an.116.012229.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3945/an.116.012229</ArticleId>
            <ArticleId IdType="pmc">PMC5015036</ArticleId>
            <ArticleId IdType="pubmed">27633107</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
